FDA Guidance for Industry: ANDA Submissions – Refuse to Receive for Lack of Justification of Impurity Limits

Title:
FDA Guidance for Industry: ANDA Submissions – Refuse to Receive for Lack of Justification of Impurity Limits
Origin/Publisher:

FDA, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM414598.pdf

Content:
This guidance is intended to assist applicants preparing to submit to the Food and Drug Administration (FDA) original abbreviated new drug applications (ANDAs) and prior approval supplements (PASs) to ANDAs for which the applicant is seeking approval of a new strength of the drug product

Go back